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Abstract
A preoperative weight loss of 8 % is a prerequisite to undergo bariatric surgery (BS) in Denmark. The aim of the present study was to evaluate the efﬁcacy
of a 7- or an 11-week low-energy diet (LCD) for achieving preoperative target weight before BS. A total of thirty obese patients (BMI 46·0 (SD 4·4) kg/m2)
followed an LCD (Cambridge Weight Plan®, 4184 kJ/d (1000 kcal/d)) for 7 or 11 weeks as preparation for BS. Anthropometric measurements including
body composition (dual-energy X-ray absorptiometry), blood parameters and blood pressure were assessed at weeks 0, 7 and 11. At week 7, the majority of
patients (77 %) had reached their target weight, and this was achieved after 5·4 (SEM 0·3) weeks. Mean weight loss was 9·3 (SEM 0·5) % (P < 0·01) and
consisted of 41·6 % fat-free mass (FFM) and 58·4 % fat mass. The weight loss was accompanied by a decrease in systolic and diastolic blood pressure
(7·1 (SEM 2·3) and 7·3 (SEM 1·8) mmHg, respectively, all P< 0·01) as well as an improved metabolic proﬁle (8·2 (SEM 1·8) % decrease in fasting glucose
(P< 0·01), 28·6 (SEM 6·4) % decrease in fasting insulin (P< 0·01), 23·1 (SEM 2·2) % decrease in LDL (P < 0·01), and 9·7 (SEM 4·7) % decrease in TAG (P<
0·05)). Weight, FFM and fat mass continued to decrease from week 7 to 11 (all P< 0·01), whereas no additional improvements was observed in the meta-
bolic parameters. Severely obese patients can safely achieve preoperative target weight on an LCD within 7 weeks as part of preparation for BS. However,
the considerable reduction in FFM in severely obese subjects needs further investigation.
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The only long-term effective treatment currently proven to
overcome severe obesity is bariatric surgery (BS)(1). Studies
have shown that the complexity of the surgical procedure
and the risk of perioperative and postoperative complications
are associated with the degree of obesity(2,3).
Beneﬁts of preoperative weight loss include a reduction in
the risk of perioperative complications by reducing visceral
adipose tissue and intrahepatic fat content, thereby minimising
the risk of having to convert to open surgery(2,4–6), shortening
of the operating time(7–10), as well as duration of hospitalisa-
tion(10,11). In addition, a preoperative weight loss may even
be associated with improved postoperative weight loss(7,10,11),
potentially by reﬂecting patients’ motivation, but also by accus-
toming patients to a lifestyle of food restriction after surgery.
Therefore, in order to optimise the safety and efﬁcacy of BS
in severely obese patients, preoperative weight loss is
preferable.
Most surgeons advise patients to lose weight prior to BS.
The Danish Ministry of Health requires an 8 % weight loss
for patients scheduled for BS(12); however, there is currently
no standard diet programme prescribed to obtain preoperative
target weight. A weight loss achieved with conventional diet
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and lifestyle changes can be very difﬁcult for some patients to
obtain, especially in a pre-speciﬁed time. In such cases, a low-
energy formula diet (LCD) with high protein content may be
an effective option. These formulas typically limit energy
intake to 3347–6276 kJ/d (800–1500 kcal/d), but contain all
essential nutrients. Low-energy, high-protein formulas are
able to induce rapid weight loss, often provide relatively
adequate satiety after a few days, and attempt to minimise
loss of fat-free mass (FFM)(13,14). As more than 300 000 BS
procedures are performed annually worldwide(15), this intensi-
ﬁes the necessity for research with focus on improving pre-
operative weight-loss strategies.
In this study we aimed to determine the efﬁcacy of an LCD
to obtain an 8 % weight loss in severely obese patients prior to
BS. Secondarily, potential health beneﬁts and side effects of
the LCD were evaluated.
Methods
This study was a part of a larger study; a detailed description
of the methods has recently been published elsewhere(16).
Study population
A total of thirty Caucasians, aged 18–65 years, with BMI ≥ 40
or BMI ≥ 35 kg/m2 combined with obstructive sleep apnoea
or hypertension approved for Roux-en-Y gastric bypass were
recruited from November 2009 to August 2011. Exclusion cri-
teria were either related to endpoints in the main study and
included diabetes mellitus, thyroid dysfunction, hypothalamic
or genetic aetiology of obesity(16), or contraindications related
to the use of the LCD: previous case of diverticulitis, past his-
tory of ventricular arrhythmias, renal dysfunction (creatinine
clearance <60 ml/min), elevated liver enzymes (alanine trans-
aminase and aspartate transaminase >3× upper normal limit),
milk protein allergy or lactose intolerance, porphyria or phenyl-
ketonuria, history of gout, breast feeding, concomitant use of
monoamine oxidase inhibitors or non-potassium-sparing
diuretics, or inability or unwillingness to comply with the LCD.
This study was conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involv-
ing human subjects were approved by the Municipal Ethical
Committee of Copenhagen/Scientiﬁc Ethics Committee of
the Metropolitan regions of Denmark (journal no.
H-2-2009-091), the Danish Data Protection Agency (journal
no. 2007-54-0296) and was registered at clinicaltrials.gov
(ClinicalTrials.gov ID NCT00939679). Written informed con-
sent was obtained from all of the subjects.
The study included a baseline visit (week 0) and two follow-
up visits at weeks 7 and 11. In order to investigate effects on
the primary endpoint of the main study (energy expend-
iture)(16), subjects were randomised to one of two groups:
group 1 scheduled for Roux-en-Y gastric bypass surgery at
week 8 (n 15), or group 2 scheduled for Roux-en-Y gastric
bypass surgery at week 12 (n 15). All participants received
an LCD for 11 weeks. In the present paper only the pre-
surgical periods will be examined: i.e. the period from week
0 to 7 (including both groups 1 and 2, n 30) and the period
from week 7 to 11 (group 2 only, n 15) (Fig. 1). Subjects
received weekly nutritional counselling from a dietitian.
Screening
Patients eligible for the study were identiﬁed by endocrinolo-
gists at Hvidovre Hospital, Copenhagen, Denmark and
referred to a screening visit at the Department of Nutrition,
Exercise and Sports, University of Copenhagen, where proto-
col details were explained and a baseline visit was scheduled
for eligible subjects.
Baseline (week 0) and follow-up visits (weeks 7 and 11)
At the baseline visit demographic data and medical history were
obtained, and patients were randomised to surgery at either
week 8 or 12. Anthropometric data were collected, a fasting
blood sample was drawn, and heart rate and blood pressure
were measured with subjects rested and in the supine position.
The LCD was initiated with their ﬁrst visit with the dietitian.
The baseline visit and the two follow-up visits were
identical.
Low-energy diet
The LCD consisted of four powder-based meals (Cambridge
Weight Plan®), 1 litre skimmed milk, 295 g vegetables and
100 g low-fat yoghurt per d, providing 4310 kJ/d (1030 kcal/d)
(48 % energy (E%) from carbohydrates, 39 E% from protein,
13 E% from fat, and ≥100 % recommended daily allowances
of all vitamins and minerals). Self-evaluated side effects and com-
pliance with the LCD was recorded at the weekly meeting with
the dietitian. Compliance was rated on a scale from 1 to 5,
with 5 indicating ‘very good compliance’.
Anthropometric measurements
Subjects were informed to wear lightweight clothing, no shoes,
have an emptied bladder and to be fasted for their anthropo-
metric assessment. Body weight was measured to the nearest
0·1 kg. Waist and hip circumferences were measured twice
to the nearest 0·5 cm and the average was used. Height was
measured to the nearest 0·5 cm using a wall-mounted digital
stadiometer. Body composition was determined by dual-energy
X-ray absorptiometry (DXA). DXA measurements were made
using half-body scans(17). The same DXA scanner (Lunar
Prodigy, Encore software version 12.3) was used throughout
the study to avoid variations in the analysis of the scan results.
However, due to weight limitations, three subjects were scanned
in a DXA scanner with larger table size and weight capacity
(Lunar iDXA, Encore software version 12.3).
Biochemical measures
Blood sampleswere collected after an overnight fast (10–12 h) and
were analysed for glucose, insulin, C-peptide, TAG, total choles-
terol, HDL, LDL and high-sensitive C-reactive protein.
Preparation and analysis of the blood samples have been described
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in detail elsewhere(16). Within- and between-assay CV were below
3·5 and 6·5 %, respectively, for all biochemical measures.
Statistical analysis
All statistical analyses were made in R version 2.14.0 (www.
r-project.org).
Descriptive data summaries (age, body weight, BMI) are pre-
sented as mean values and standard deviations. The efﬁcacy of
the LCD on all endpoints was modelled in a mixed linear model
with week as ﬁxed effect and subject as random effect. All ana-
lyses were based on intention-to-treat with baseline observations
carried forward for missing data (n 2), except for body weight
where the last observation (measured at the weekly meeting
with the dietitian) was carried forward for missing data.
Subanalyses were modelled in a mixed linear model including
a week × group interaction and with subject as random effect.
Data are presented as mean values with their standard errors.
P values correspond to likelihood ratio tests and P values
<0·05 were considered signiﬁcant. Figures and parameters
were based on raw data, whereas conclusions (P values)
were based on model estimations.
Power calculations estimating the number of subjects to be
included were based on the primary endpoint of the main
study(16). However, a sample size calculation, based on data
from a previous study using a 3347–4184 kJ (800–1000 kcal)
LCD for 8 weeks(18), showed that with our sample size we
were powered to detect an 8 % weight loss in obese subjects
(corresponding to a mean weight loss of 11·1 kg, an SD of
3·3 kg and a minimal relevant difference of 8 kg (8 % weight
loss); α = 0·05, β = 0·8).
Results
Descriptive data
In all, eight males and twenty-two females were included in the
study. Average age was 38·8 (SD 10·4) years, with a mean body
weight at baseline of 135·1 (SD 19·2) kg and BMI of 46·0
(SD 4·4) kg/m2. Two subjects dropped out before the ﬁrst
follow-up visit (week 7), due to personal problems and an
inability to comply with the LCD.
Weight loss
The mean weight loss at week 7 was 9·3 (SEM 0·5) %, corre-
sponding to a weight loss of 12·7 (SEM 0·8) kg (Fig. 2).
Of the included patients, 77 % reached their preoperative
target weight, and this was on average achieved at week 5·4
Fig. 1. Overview of the study design. Since the design of the main study was a controlled trial, the participants were randomised to Roux-en-Y gastric bypass (RYGB)
surgery in week 8 (group 1) or week 12 (group 2). Participants followed a low-energy formula diet from week 0 to week 11.
Fig. 2. Weekly weight loss (%) measured from week 0 to 7 (n 30; groups 1 and 2; ○) and from week 0 to 11 in group 2 only (n 15; X). Group 1 were operated in week
8; group 2 was operated in week 12. Values are means, with standard errors represented by vertical bars.
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(SEM 0·3). Weight loss in the group that reached their target
weight before week 7 (n 23) was 10·2 (SEM 0·3) %, correspond-
ing to a weight reduction of 14·1 (SEM 0·7) kg, whereas mean
weight loss for the remaining subjects in week 7 (n 7) was 6·1
(SEM 0·9) %, corresponding to a weight reduction of 7·9 (SEM
1·2) kg. Percentage weight loss at week 7 did not predict
percentage excess weight loss 18 months postoperatively
(r −0·40; P = 0·07).
A further 3·9 (SEM 0·5) % reduction in body weight was
observed from week 7 to 11 in the ﬁfteen patients scheduled
for BS in week 12 (P < 0·01). All of the twenty-eight subjects
who completed the follow-up visits reached their target weight
prior to surgery in weeks 8 and 12, respectively. Mean dietary
compliance was 4·3 (SEM 0·1) from week 0 to 7, and remained
unchanged until week 11 (4·1 (SEM 0·2); P= 0·16). Compliance
was positively associated with percentage weight loss from
week 0 to 7 (r 0·59; P < 0·001).
FFM and fat mass comprised 41·6 and 58·4 % of the weight
loss from week 0 to 7, respectively. A further reduction in both
fat mass and FFM (5·0 (SEM 0·8) and 2·3 (SEM 0·7) %, respect-
ively) was observed from week 7 to 11 (both P < 0·01).
A post hoc analysis comparing patients with higher initial body
weight (HIBW) (above the 50th percentile, corresponding to
body weight≥135 kg) and patients with lower initial body weight
(LIBW) (below the 50th percentile, corresponding to body
weight <135 kg) was carried out. This analysis revealed that the
HIBW group experienced a greater relative weight loss (9·8
(SEM 0·5) v. 8·7 (SEM 0·7) %; P< 0·01) and that FFM accounted
for a larger part of the weight loss compared with patients in the
LIBW group (46 v. 36 %, respectively, P= 0·02, corresponding
to 6·3 (SEM 1·0) and 3·5 (SEM 0·7) kg, respectively, Fig. 3).
Blood parameters
Fromweek 0 to 7 fasting glucose, insulin andC-peptidedecreased
by 8·2 (SEM 1·8), 28·6 (SEM 6·4) and 15·4 (SEM 4·5) %,
respectively (all P< 0·01). TAG, total cholesterol, HDL
and LDL decreased by 9·7 (SEM 4·7), 21·7 (SEM 2·0), 23·5
(SEM 2·5) and 23·1 (SEM 2·2) %, respectively (Table 1; all
P< 0·05). No further decrease in any of these parameters was
observed from week 7 to 11.
Heart rate and blood pressure
Heart rate, systolic and diastolic blood pressure decreased by 4·9
(SEM 1·3) beats/min, 7·1 (SEM 2·3) and 7·3 (SEM 1·8) mmHg,
respectively (all P< 0·01), with no further decrease observed
from week 7 to 11. At baseline, six patients had blood pressure
above the normal range (>140/90 mmHg), and only one of
these patients was pharmacologically treated for this. Blood
pressure normalised in ﬁve of these six patients at week 7. An
additional ﬁve patients were on antihypertensive medication
with blood pressure within the normal range at baseline.
Medication was withdrawn in one of these patients at week 7.
Side effects
The most commonly reported side effects were headache,
fatigue, constipation, dizziness and upper respiratory infections
(reported by 57, 50, 43, 33 and 30 %, respectively). Other less-
reported side effects included cold intolerance, hunger,
abdominal pain, irritability, dry skin, diarrhoea, ﬂatulence
and bad breath. No severe adverse events were reported.
Discussion
In the present study, we demonstrated that for the vast major-
ity of patients, it is possible to rapidly achieve an 8 % preopera-
tive weight loss by implementation of a 7-week LCD in
combination with dietary counselling. The mean weight loss
of 9·3 (SEM 0·5) % is comparable with that found by
Papadaki et al. reporting a weight loss of 11·1 % in overweight
and obese adults who followed an LCD for 8·2 weeks(18). Our
patients generally reported good compliance with the LCD
during the 7 weeks. Although compliance relies on self-
evaluated measures with inherent limitations in terms of valid-
ity, we found that reported compliance explained 35 % of the
variation in weight loss at week 7. With a dropout rate of only
7 %, an LCD management approach seems to be a viable
option for severely obese patients to obtain preoperative target
weight. Compliance with LCD has been shown to decrease
over time(2); however, reported compliance was unchanged
from week 7 to 11 and weight loss continued, indicating that
an LCD programme for 11 weeks is still reasonable from a
compliance perspective. The baseline characteristics and
reported compliance of the seven subjects who failed to
achieve preoperative target weight at week 7 were not different
from the rest of the study group (data not shown).
Although loss of FFM is unavoidable in a weight-loss pro-
cess based on dietary changes in patients with obesity(19), a
relative preservation of FFM is beneﬁcial due to its higher
metabolic activity compared with fat(19,20). It has been sug-
gested that the acceptable amount of FFM loss in obese sub-
jects (mean BMI = 35 kg/m2) is within the range of 22–30 %
Fig. 3. Fat-free mass (▒) and fat mass (░) loss in patients with higher initial
body weight (HIBW; above the 50th percentile corresponding to body weight
≥135 kg) and patients with lower initial body weight (LIBW; below the 50th per-
centile corresponding to body weight <135 kg). Values are means, with stand-
ard errors represented by vertical bars. A mixed linear model was used to test
for differences between the groups. There was a significant difference
between the LIBW and HIBW groups.
4
journals.cambridge.org/jns
of total weight loss(21), and studies evaluating the effect of
energy-deﬁcient diets (2092–5021 kJ (500–1200 kcal)) in
obese subjects typically report loss of FFM to account for
19–36 % of total weight loss(18,22–26). Thus, the weight loss
induced by the LCD in the present study resulted in a consid-
erable reduction of FFM (41·6 % of total weight loss). The
reduction in FFM is high, especially considering the relatively
high protein content (39 E%) of the LCD. However, it is ques-
tionable whether the LCD can be deﬁned as a high-protein
LCD, when applied in severely obese patients. A daily protein
intake of 0·83 g/kg per d is recommended in healthy adults in
energy balance(27), but there are no formal recommendations
for protein requirement during weight loss in the severely
obese. As the mean protein intake in the present study was
0·75 (SEM 0·10) g/kg per d at baseline, it can be argued that
the protein intake during the LCD cannot be considered
high in this population. In addition, the large negative energy
balance in these severely obese patients might be an underlying
cause of the excessive loss of FFM. In a systematic review,
Chaston et al.(19) reported that the loss of FFM following diet-
ary interventions increased with the degree of energy deﬁcit
and consequently the rate of weight loss. This is supported
by our subanalysis, which revealed that patients with HIBW
experienced a greater loss of FFM compared with patients
with LIBW (46 v. 36 %). Comparing the protein intake/kg
body weight per d at baseline in the HIBW and the LIBW,
we found a lower intake in the HIBW (0·66 (SEM 0·06) v.
0·84 (SEM 0·05) g/kg per d; P < 0·01). These results indicate
that a 4184 kJ (1000 kcal) LCD with a protein content of 39
E% is not sufﬁcient for preservation of FFM in obese patients
in negative energy balance, especially not in severely obese
patients with an initial body weight >135 kg.
No severe adverse effects of the LCD were reported. The
most commonly reported side effects were headache, fatigue,
constipation and dizziness, which are well-known side effects
following an LCD(28–30). Levels of fasting glucose, insulin,
C-peptide, cholesterol, TAG, HDL and LDL decreased
from week 0 to 7, as previously demonstrated(31,32).
Interestingly, the period from week 7 to 11 did not induce
any additional beneﬁcial effects, suggesting that energy restric-
tion has an immediate effect on these blood parameters. In
agreement with previous ﬁndings(28), the LCD was also asso-
ciated with a reduction in systolic and diastolic blood pressure,
and four out of ﬁve subjects falling into the hypertensive range
at baseline were normotensive at week 7. We found no asso-
ciation between preoperative weight loss and weight loss 18
months postoperatively. The evidence is inconclusive on
whether or not a relationship exists. Consistent with our ﬁnd-
ings, some studies report no association(9,33,34), whereas others
have found a beneﬁcial effect of preoperative weight loss on
postoperative weight loss(7,10,11). Taken together, these results
suggest that a 7-week preoperative LCD treatment optimises
the health of patients prior to surgery, but has no effect on
long-term weight outcome.
As nutritional counselling is an important aspect in the treat-
ment of obesity(35,36), a limitation of the present study is that
the results may not be directly applicable to candidates for
BS who do not receive weekly nutritional counselling and
encouragement from an experienced health professional.
Furthermore, the exclusion of diabetic patients and subjects
who were unwilling to comply with the LCD could have
affected our results, as this group may be less prone to weight
loss(37). Another limitation is the DXA, which has not been
fully evaluated as an assessment tool for body composition
in severely obese patients, and has been reported not to pro-
vide valid data under dynamic weight loss due to inaccurate
assumptions of a constant FFM hydration(38).
In conclusion, our results suggest that it is possible to obtain
preoperative weight loss of 8 % with an LCD within 7 weeks.
The weight loss at week 7 was accompanied with an improved
Table 1. Changes in anthropometric and biochemical parameters after a 7-week low-energy formula diet treatment in thirty obese patients
(Mean values with their standard errors)
Week 0 (n 30) Week 7 (n 30) Change week 0–7
Outcome Mean SEM Mean SEM Mean SEM
Body weight (kg) 135·1 3·5 122·4 3·0 −12·7** 0·8
BMI (kg/m2) 46·0 0·8 41·8 0·7 −4·2** 0·2
Hip circumference (cm) 143·4 2·3 134·2 2·2 −9·2** 1·3
Waist circumference (cm) 129·9 2·5 119·8 2·4 −10·1** 0·9
FFM (kg) 66·2 2·0 61·3 1·7 −4·9** 0·6
FM (kg) 67·4 2·2 60·6 2·0 −6·9** 0·7
Glucose (mmol/l) 5·9 0·2 5·4 0·1 −0·5** 0·1
Insulin (pmol/l) 131·9 16·5 80·5 7·2 −51·4** 13·9
C-peptide (pmol/l) 1192·6 84·5 934·2 36·9 −258·4** 76·6
hs-CRP (mg/l) 11·8 1·5 8·5 2·0 −3·3** 1·1
TAG (mmol/l) 1·6 0·2 1·3 0·1 −0·3* 0·1
Total cholesterol (mmol/l) 5·4 0·2 4·2 0·1 −1·2** 0·1
HDL (mmol/l) 1·2 0·1 0·9 0·1 −0·3** 0·1
LDL (mmol/l) 3·4 0·1 2·6 0·1 −0·8** 0·1
Systolic BP (mmHg) 126·3 2·7 119·1 2·0 −7·1** 2·3
Diastolic BP (mmHg) 87·4 2·0 80·1 1·7 −7·3** 1·8
HR (beats/min) 67·8 1·7 62·9 1·3 −4·9** 1·3
FFM, fat-free mass; FM, fat mass; hs-CRP, high-sensitive C-reactive protein; BP, blood pressure; HR, heart rate.
Mean value of change from week 0 to 7 was significant: *P < 0·05, **P < 0·01.
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metabolic proﬁle and a reduction in blood pressure, with no fur-
ther improvements after an additional 3·9 % weight loss at week
11. The mechanisms behind the excessive reduction in FFM in
highly obese subjects following LCD needs further investiga-
tion, including the potential for optimisation of LCD formulas
used in order to limit loss of metabolically active tissue.
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